Adicet Bio, Inc.

Equities

ACET

US0070021086

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.68 ^USD	-7.18%		-13.85%	-11.11%

Apr. 22	Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	CI
Mar. 26	North American Morning Briefing : Markets Steady -2-	DJ

Adicet Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 09, 2023 at 04:21 pm EDT

Adicet Bio, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 32.4 million compared to USD 22.54 million a year ago. Basic loss per share from continuing operations was USD 0.75 compared to USD 0.56 a year ago.
For the six months, net loss was USD 63.28 million compared to USD 17.92 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 0.45 a year ago.

Latest news about Adicet Bio, Inc.

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting	Apr. 22	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Adicet Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
JonesTrading Upgrades Adicet Bio to Buy From Hold, Price Target is $6	Feb. 14	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Jan. 23	MT
Adicet Bio Prices $85.2 Million Share Offering	Jan. 23	MT
Adicet Bio Launches Securities Offering; Shares Rise After-Hours	Jan. 22	MT
Transcript : Adicet Bio, Inc. - Special Call	Jan. 04
Adicet Bio, Inc.(NasdaqGM:ACET) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting	Dec. 10	CI
Adicet Bio, Inc. Announces Board Changes	Nov. 13	CI
Wedbush Lowers Adicet Bio's PT to $5 From $17, Adjusts Model to Reflect More Focused Strategy; Retains Outperform Rating	Nov. 09	MT
Adicet Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
North American Morning Briefing : Stock Futures -2-	23-08-16	DJ
HC Wainwright Adjusts Adicet Bio Price Target to $26 From $38, Maintains Buy Rating	23-08-11	MT
Adicet Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors	23-07-11	CI
Insider Buy: Adicet Bio	23-06-29	MT
North American Morning Briefing : Chip Stocks Take -2-	23-06-28	DJ
Guggenheim Downgrades Adicet Bio to Neutral From Buy	23-06-27	MT
JonesTrading Downgrades Adicet Bio to Hold From Buy	23-06-27	MT
JMP Securities Downgrades Adicet Bio to Market Perform From Market Outperform	23-06-27	MT
Wedbush Cuts Adicet Bio's Price Target to $17 From $30 to be Conservative as Focus Remains on Post CAR-T Setting; Keeps Outperform Rating	23-06-27	MT
Adicet Bio Reports Positive Phase 1 Data for Treatment of Non-Hodgkin's Lymphoma; Shares Drop Premarket	23-06-27	MT

Chart Adicet Bio, Inc.

Duration

Period

More charts

Company Profile

Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.68 USD

Average target price

9.6 USD

Spread / Average Target

+471.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADICET BIO, INC.	-11.11%	138M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research